JYC reports a research grant from Bristol-Myers Squibb, consulting fees from Legion Healthcare Partners, and being a shareholder for Global Oncology One. JWW reports research support from GlaxoSmithKline, Bristol-Myers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, Varian, and Checkmate Pharmaceuticals. JWW serves or has served on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech, and Nanorobotix. JWW serves as consultant for Lifescience Dynamics Limited. JWW has or had speaking engagements for Ventana Medical Systems, US Oncology, Alkermes, and Boehringer Ingelheim. JWW holds or held stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotix, OncoResponse, and RefleXion. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong University, The Korea Society of Radiology, Aileron Therapeutics, and Ventana. JWW has the following patents: MP470 (amuvatinib), MRX34 regulation of PDL1, and XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopalTM. SCF reports research grants from Merck, Varian, Bristol-Myers Squibb, Regeneron, Eisai, and Eli Lilly; consulting fees from Accuray, Boehringer Ingelheim, Roche, Genentech, AstraZeneca, and Viewray; support for attending meetings or travel from Bayer, Bristol-Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, Eisai, AstraZeneca, Medlmmune, Merck US, EMDSerono/Merck, and Accuray. VV declares no competing interests.